Rabbit Anti-Human VEGFR-3/FLT-4
Slide this table
| Cat-Nr. | 102-PA22 |
| Size | 200 µg |
| Price | 240 € |
| Category | Polyclonal Antibody |
| Clone Nr. | Rabbit IgG |
| Species Reactivity | Human |
| Formulation | lyophilized |
| Buffer | PBS |
| Reconstitution | Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml. |
| Stability and Storage | The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots. |
| Preparation | Produced from sera of rabbits immunised with highly pure recombinant human soluble VEGFR-3/FLT-4 (D1-D7). Anti-human VEGFR-3/FLT-4 was purified by antigen-affinity chromatography with immobilised soluble VEGFR-3/FLT-4. |
| Antigen | Recombinant human sFLT-4 (D1-7) (RT #S01-017) |
| Application | WB, IP, E, IHC (C) |
| Synonyms | vascular endothelial growth factor receptor-3; FLT4; PCL; LMPH1A; VEGFR3; fms-related tyrosine kinase 4 |
| Description | Receptor tyrosine Kinase VEGFR-3, also known as FLT4, together with VEGFR1 (FIT1) and VEGFR2 (KDR/Flk-1), are the receptors for vascular endothelial growth factors (VEGF). The VEGFR family belongs to the class II subfamily of receptor tyrosine kinases (RTKs), containing a large extracellular region which is composed of seven Ig-like domains (D1–D7), a single transmembrane (TM) helix and cytoplasmic region with a tyrosine kinase activity. In VEGFR-3, the fifth Ig homology domain is proteolytically cleaved which results in polypeptides remain linked by two disulfide bonds. VEGFR-3 is widely expressed on all endothelia cells in early embryogenesis, while, in adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. VEGF-C and VEGF-D activation of VEGFR-3 plays an important role in the formation of the lymphatic vessel system. |
| Uniprot ID | P35916 |
| Protein RefSeq | NP_002011 |
| mRNA RefSeq | NM_002020 |
Figures
Immunofluorescence staining of human VEGFR-3/FLT-4 (red) in hFlt4-transfected MG63 cells. Monoclonal mouse anti-human FLT-4 #9D9 [Cat# 101-M36] and polyclonal rabbit anti-human FLT-4 (D) [Cat# 102-PA22]: A and C are negative control with secondary antibody only; B (mAb) and D (pAb) with specific antibodies against human FLT-4.
The experiment was performed by the research group of Dr. Wolfgang Holnthoner, Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Austrian Cluster for Tissue Regeneration, Donaueschingenstrasse 13, A-1200 Vienna, Austria
IHC with cryo sections of human spleen.
The experiment was performed by Prof. Dr. Birte Steiniger, Institute of Anatomy and Cell Biology Robert-Koch-Str. 8, D-35037 Marburg, Germany
FACS analysis with primary human dermal lymphatic endothelial cells (HDLEC).
Western analysis of recombinant human soluble VEGFR3/FLT-4 using a rabbit anti-human FLT-4 antibody [Cat# 102-PA22]. Lane 1 and 2: purified proteins; Lane 4 and 5: insect cells supernatant.
Reference
- Endothelial EphB4 maintains vascular integrity and transport function in adult heart. G. Luxán et al., eLife. 2019; 8: e45863.
- Functional Importance of a Proteoglycan Coreceptor in Pathologic Lymphangiogenesis. S. C. Johns et al., Circ Res. 2016 Jul 8; 119(2): 210–221.
- The defect of both angiogenesis and lymphangiogenesis is involved in preeclampsia. Liu H et al., Placenta. 2015 Mar;36(3):279-86.
- Lymphatic Endothelial Heparan Sulfate Deficiency Results in Altered Growth Responses to Vascular Endothelial Growth Factor-C (VEGF-C). X. Yin et al., J Biol Chem. 2011 Apr 29; 286(17): 14952–14962.
All prices plus VAT + possible delivery charges